BIOLINERX LTD-SPONS ADR (BLRX) Stock News
NASDAQ:BLRX - Nasdaq - US09071M2052 - ADR
BLRX Latest News and Analysis
What's going on in today's session
Which stocks are experiencing notable movement on Friday?
Friday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Which stocks are most active on Thursday?
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks in Tuesday's session
These stocks are moving in today's session
Which stocks are experiencing notable movement on Monday?
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
BioLineRx Announces $10 Million Registered Direct Offering
/PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing...
Curious about the stocks that are showing activity before the opening bell on Friday?
What's going on in Friday's pre-market session
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as...
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the second quarter of 2024.T...
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the first quarter of 2024.Bi...
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces $6 Million Registered Direct Offering
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...